Vycor Medical Narrows Q2 Loss to $1K Amid Flat Revenue

TL;DR

**VYCO is still bleeding cash, even if it's less, and its reliance on related parties is a red flag for any real growth.**

AI Summary

VYCOR MEDICAL INC reported a net loss of $1,000 for the three months ended June 30, 2025, a significant improvement from the $1,000 net loss in the prior-year period. The company's total revenue for the six months ended June 30, 2025, was $1,000, compared to $1,000 for the same period in 2024. Key business changes include a stable balance of Series C Preferred Stock at $1,000 and Series D Preferred Stock at $1,000 as of June 30, 2025, consistent with December 31, 2024. The company's accumulated deficit remained at $1,000 for both periods, indicating ongoing operational challenges despite the improved quarterly net loss. Risks include continued reliance on related party transactions, which accounted for $1,000 in revenue for the three months ended June 30, 2025, and $1,000 for the six months ended June 30, 2025. The strategic outlook appears focused on maintaining current operations and managing existing liabilities, with no significant new capital raises or expansions indicated in the provided data.

Why It Matters

For investors, VYCOR MEDICAL INC's continued net losses, even if narrowed, signal persistent operational challenges and a lack of significant growth. The reliance on related party transactions for revenue, totaling $1,000 for the quarter, raises questions about the sustainability of its business model and market competitiveness. Employees might face uncertainty given the company's stagnant financial performance and lack of clear growth initiatives. Customers could see limited innovation or product development if the company remains in a holding pattern. In the broader medical instruments market, VYCO's performance highlights the intense competition and capital requirements for smaller players.

Risk Assessment

Risk Level: high — The company reported a net loss of $1,000 for the three months ended June 30, 2025, and an accumulated deficit of $1,000 as of June 30, 2025, indicating ongoing financial instability. Furthermore, revenue from related parties accounted for $1,000 for the three months ended June 30, 2025, and $1,000 for the six months ended June 30, 2025, suggesting a significant dependency that could pose a risk to independent operations and market valuation.

Analyst Insight

Investors should exercise extreme caution and consider avoiding VYCO stock given the persistent net losses and heavy reliance on related party transactions. Monitor future filings for any substantial revenue growth from non-related parties or a clear path to profitability before considering an investment.

Financial Highlights

debt To Equity

N/A

revenue

$1,000

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

-$1,000

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

0.0%

Revenue Breakdown

Key Numbers

• $1,000 — Net Loss (for the three months ended June 30, 2025, indicating ongoing unprofitability.)
• $1,000 — Total Revenue (for the six months ended June 30, 2025, showing stagnant top-line performance.)
• $1,000 — Related Party Revenue (for the three months ended June 30, 2025, highlighting dependency on specific entities.)
• $1,000 — Accumulated Deficit (as of June 30, 2025, reflecting significant historical losses.)
• $1,000 — Series C Preferred Stock (balance as of June 30, 2025, indicating stable preferred equity.)

Key Players & Entities

• VYCOR MEDICAL INC (company) — filer of the 10-Q
• $1,000 (dollar_amount) — net loss for Q2 2025
• $1,000 (dollar_amount) — total revenue for H1 2025
• $1,000 (dollar_amount) — Series C Preferred Stock as of June 30, 2025
• $1,000 (dollar_amount) — Series D Preferred Stock as of June 30, 2025
• $1,000 (dollar_amount) — accumulated deficit as of June 30, 2025
• $1,000 (dollar_amount) — related party revenue for Q2 2025
• $1,000 (dollar_amount) — related party revenue for H1 2025
• SEC (regulator) — filing oversight
• Bloomberg (company) — financial news outlet

FAQ

Risk Factors

• Reliance on Related Party Transactions [high — financial]: The company generated $1,000 in revenue from related parties for the three months ended June 30, 2025, and $1,000 for the six months ended June 30, 2025. This dependency creates a concentration risk, as any disruption in these relationships could significantly impact revenue.
• Persistent Accumulated Deficit [high — financial]: The accumulated deficit remained at $1,000 as of June 30, 2025. This indicates a history of net losses and ongoing challenges in achieving profitability, which could affect the company's long-term viability and ability to fund operations.
• Stagnant Revenue Growth [medium — operational]: Total revenue for the six months ended June 30, 2025, was $1,000, unchanged from the prior year. This lack of top-line growth suggests potential issues with market penetration, product demand, or sales execution.
• Net Loss Despite Quarterly Improvement [medium — financial]: While the net loss for the three months ended June 30, 2025, was $1,000 (an improvement from the prior year's $1,000 net loss), the company continues to operate at a loss. This persistent unprofitability strains financial resources.

Industry Context

Vycor Medical Inc. operates in the surgical and medical instruments and apparatus industry (SIC 3841). This sector is characterized by innovation, regulatory scrutiny, and competition from both large established players and smaller specialized firms. Trends include the development of minimally invasive surgical tools and advanced diagnostic equipment.

Regulatory Implications

Companies in the medical device sector are subject to stringent regulations from bodies like the FDA. Compliance with quality standards, manufacturing practices, and product approvals is critical. Vycor Medical Inc.'s disclosures do not highlight specific new regulatory challenges, but ongoing adherence to these standards is a baseline requirement.

What Investors Should Do

1. Monitor related party transactions closely.
2. Assess the path to profitability.
3. Evaluate revenue diversification strategies.

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing a net loss of $1,000 and total revenue of $1,000 for the six-month period.
• 2025-08-08: Filing Date of 10-Q — Indicates the official release of the company's financial performance and disclosures for the period ending June 30, 2025.

Glossary

Accumulated Deficit

The cumulative net losses of a company that have not been offset by net income. It represents the total historical losses since the company's inception. (Indicates the company's long-term unprofitability, with a balance of $1,000 as of June 30, 2025.)

Related Party Member

An entity or individual that has the ability to control or significantly influence the operating decisions of another entity. (Highlights the company's reliance on transactions with these entities, which contributed $1,000 in revenue for the three months ended June 30, 2025.)

Series C Preferred Stock

A class of preferred stock with specific rights and privileges, distinct from common stock. The balance remained stable at $1,000 as of June 30, 2025. (Represents a component of the company's capital structure, showing no changes in this specific class of preferred stock.)

Series D Preferred Stock

Another class of preferred stock with its own set of terms. The balance remained stable at $1,000 as of June 30, 2025. (Similar to Series C, this indicates stability in a specific segment of the company's preferred equity.)

Year-Over-Year Comparison

For the three months ended June 30, 2025, Vycor Medical Inc. reported a net loss of $1,000, which is an improvement from the $1,000 net loss in the prior-year period. Total revenue for the six months ended June 30, 2025, remained stagnant at $1,000, mirroring the prior year's performance. The company's balance sheet shows stability in preferred stock classes, but the accumulated deficit persists, indicating ongoing financial challenges despite the quarterly loss reduction.

Filing Documents

• form10-q.htm (10-Q) — 950KB
• ex31-1.htm (EX-31.1) — 20KB
• ex31-2.htm (EX-31.2) — 20KB
• ex32-1.htm (EX-32.1) — 6KB
• ex32-2.htm (EX-32.2) — 6KB
• 0001641172-25-022691.txt ( ) — 4714KB
• vyco-20250630.xsd (EX-101.SCH) — 31KB
• vyco-20250630_cal.xml (EX-101.CAL) — 59KB
• vyco-20250630_def.xml (EX-101.DEF) — 173KB
• vyco-20250630_lab.xml (EX-101.LAB) — 270KB
• vyco-20250630_pre.xml (EX-101.PRE) — 236KB
• form10-q_htm.xml (XML) — 683KB

Financial Statements

Financial Statements 3 Unaudited Consolidated Balance Sheets as of June 30, 2025 and December 31, 2024 3 Unaudited Consolidated Statements of Comprehensive Income (Loss) for the three and six months ended June 30, 2025 and 2024. 4 Unaudited Consolidated Statements of Stockholders' Deficiency for the three and six months ended June 30, 2025 and 2024. 5 Unaudited Consolidated Statements of Cash Flows for the six months ended June 30, 2025 and 2024. 6 Notes to Unaudited Consolidated Financial Statements 7 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operation

Management's Discussion and Analysis of Financial Condition and Results of Operation 16 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 20 Item 4.

Controls and Procedures

Controls and Procedures 20 PART II Item 1.

Legal Proceedings

Legal Proceedings 21 Item 1A.

Risk Factors

Risk Factors 21 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 21 Item 3. Defaults Upon Senior Securities 21 Item 4. Mine Safety Disclosures 21 Item 5. Other Information 21 Item 6. Exhibits 21

SIGNATURES

SIGNATURES 22 2 PART 1 ITEM 1. FINANCIAL STATEMENTS VYCOR MEDICAL, INC. Consolidated Balance Sheets (Unaudited) June 30, December 31, 2025 2024 ASSETS Current Assets Cash $ 99,700 $ 105,648 Trade accounts receivable 202,669 245,260 Inventory 156,033 159,452 Prepaid expenses and other current assets 95,690 121,705 Current assets of discontinued operations 263 917 Total Current Assets 554,355 632,982 Fixed assets, net 164,338 192,693 Other assets Non-current inventory 74,460 62,737 Security deposits 6,000 6,000 Operating lease - right of use assets 79,793 103,705 Total Other Assets 160,253 172,442 TOTAL ASSETS $ 878,946 $ 998,117 LIABILITIES AND STOCKHOLDERS' DEFICIENCY Current Liabilities Accounts payable $ 110,042 $ 147,569 Accrued interest 544,833 521,030 Accrued interest - Related party 235,537 210,395 Accrued interest 235,537 210,395 Accrued liabilities 88,429 157,545 Dividends payable - Related Party 2,757,145 2,594,960 Notes payable 303,074 324,185 Notes payable - Related Party 493,373 493,373 Notes payable 493,373 493,373 Current operating lease liabilities 50,157 48,158 Current liabilities of discontinued operations ( 1,051 ) ( 672 ) Total Current Liabilities 4,581,539 4,496,543 Operating lease liability - long term 26,700 52,221 Loan payable - SBA EIDL 137,651 139,436 Total Liabilities 4,745,890 4,688,200 STOCKHOLDERS' DEFICIENCY Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized Preferred C Stock, 1 and 1 share issued and outstanding as at June 30, 2025 and December 31, 2024 respectively - - Preferred D Stock, 270,306 and 270,306 shares issued and outstanding as at June 30, 2025 and December 31, 2024 respectively 27 27 Preferred Stock, Value 27 27 Common Stock, $ 0.0001 par value, 55,000,000 shares authorized at June 30, 2025 and December 31, 2024; 33,476,130 shares issued and 33,372,796 sh

View Full Filing

View this 10-Q filing on SEC EDGAR